Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction

J. Silvain, T. Rakowski, B. Lattuca, Z. Liu, L. Bolognese, P. Goldstein, C. Hamm, JF. Tanguay, J. Ten Berg, P. Widimsky, D. Miller, JJ. Portal, JP. Collet, E. Vicaut, G. Montalescot, D. Dudek, ACCOAST Investigators,

. 2019 ; 73 (8) : 906-914. [pub] 20190305

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006558

BACKGROUND: In the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial, the prasugrel pre-treatment strategy versus placebo was associated with excess bleeding complications and no improved ischemic outcome in non-ST-segment elevation myocardial infarction (MI). Whether patients with the longest pre-treatment duration had an ischemic benefit is unknown. OBJECTIVES: This pre-specified analysis of the ACCOAST trial aimed to assess the effect of pre-treatment duration with prasugrel (time from randomization to angiography) on outcomes. METHODS: Within the 4,033 patients randomized in the ACCOAST trial, pre-treatment duration was available in 4,001 patients (99.2%). The population of the trial was divided into quartiles of pre-treatment duration (0.1 to 2.5 h, 2.5 to 3.9 h, 3.9 to 13.6 h, and >13.6 h) with an evaluation of the primary efficacy endpoint of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use. Secondary efficacy outcomes including cardiovascular death, MI, or stroke; all-cause death; stent thrombosis and safety outcomes (all coronary artery bypass graft [CABG] or non-CABG TIMI [Thrombolysis In Myocardial Infarction] major bleeding) were also evaluated at 7 days. RESULTS: The primary efficacy outcome of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use did not differ between the quartiles of pre-treatment duration in the trial population (p = 0.17 for interaction). None of the secondary efficacy outcomes were found to be dependent on pre-treatment duration. The safety outcome of all CABG or non-CABG TIMI major bleeding did not differ between the quartiles of pre-treatment duration (p = 0.37 for interaction). CONCLUSIONS: In non-ST-segment elevation MI patients, the excess risk of bleeding and the absence of ischemic benefit were consistent across the quartiles of increasing duration of prasugrel pre-treatment. (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction [ACCOAST]; NCT01015287).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006558
003      
CZ-PrNML
005      
20200526084523.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2018.11.055 $2 doi
035    __
$a (PubMed)30819358
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Silvain, Johanne $u Sorbonne University, ACTION Study Group, INSERM UMRS 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: https://twitter.com/Docjohanne.
245    10
$a Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction / $c J. Silvain, T. Rakowski, B. Lattuca, Z. Liu, L. Bolognese, P. Goldstein, C. Hamm, JF. Tanguay, J. Ten Berg, P. Widimsky, D. Miller, JJ. Portal, JP. Collet, E. Vicaut, G. Montalescot, D. Dudek, ACCOAST Investigators,
520    9_
$a BACKGROUND: In the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial, the prasugrel pre-treatment strategy versus placebo was associated with excess bleeding complications and no improved ischemic outcome in non-ST-segment elevation myocardial infarction (MI). Whether patients with the longest pre-treatment duration had an ischemic benefit is unknown. OBJECTIVES: This pre-specified analysis of the ACCOAST trial aimed to assess the effect of pre-treatment duration with prasugrel (time from randomization to angiography) on outcomes. METHODS: Within the 4,033 patients randomized in the ACCOAST trial, pre-treatment duration was available in 4,001 patients (99.2%). The population of the trial was divided into quartiles of pre-treatment duration (0.1 to 2.5 h, 2.5 to 3.9 h, 3.9 to 13.6 h, and >13.6 h) with an evaluation of the primary efficacy endpoint of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use. Secondary efficacy outcomes including cardiovascular death, MI, or stroke; all-cause death; stent thrombosis and safety outcomes (all coronary artery bypass graft [CABG] or non-CABG TIMI [Thrombolysis In Myocardial Infarction] major bleeding) were also evaluated at 7 days. RESULTS: The primary efficacy outcome of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use did not differ between the quartiles of pre-treatment duration in the trial population (p = 0.17 for interaction). None of the secondary efficacy outcomes were found to be dependent on pre-treatment duration. The safety outcome of all CABG or non-CABG TIMI major bleeding did not differ between the quartiles of pre-treatment duration (p = 0.37 for interaction). CONCLUSIONS: In non-ST-segment elevation MI patients, the excess risk of bleeding and the absence of ischemic benefit were consistent across the quartiles of increasing duration of prasugrel pre-treatment. (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction [ACCOAST]; NCT01015287).
650    _2
$a příčina smrti $x trendy $7 D002423
650    _2
$a koronární angiografie $x metody $7 D017023
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a elektrokardiografie $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu bez ST elevací $x diagnóza $x mortalita $x terapie $7 D000072658
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $7 D010975
650    _2
$a prasugrel hydrochlorid $x aplikace a dávkování $7 D000068799
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rakowski, Tomasz $u Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
700    1_
$a Lattuca, Benoit $u Sorbonne University, ACTION Study Group, INSERM UMRS 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France; Service de Cardiologie, Centre Hospitalier Universitaire Nîmes, ACTION Study Group, Université Montpellier, Montpellier, France.
700    1_
$a Liu, Zhenyu $u Department of Cardiology, Peking Union Medical College Hospital, Beijing, China.
700    1_
$a Bolognese, Leonardo $u Cardiovascular and Neurological Department, Azienda Ospedaliera, Arezzo, Italy.
700    1_
$a Goldstein, Patrick $u SAMU and Emergency Department, Lille University Hospital, Lille, France.
700    1_
$a Hamm, Christian $u Kerckhoff Heart and Thorax Center, Bad Nauheim and Medical Clinic I, University of Giessen, Giessen, Germany.
700    1_
$a Tanguay, Jean-Francois $u Montreal Heart Institute, Montreal University, Montreal, Quebec, Canada.
700    1_
$a Ten Berg, Jur $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
700    1_
$a Widimsky, Petr $u Third Medical Faculty of Charles University and University Hospital Royal Vineyards, Prague, Czech Republic.
700    1_
$a Miller, Debra $u Eli Lilly and Company, Indianapolis, Indiana.
700    1_
$a Portal, Jean-Jacques $u Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisière (ACTION Study Group, AP-HP, Université Paris 7), Paris, France.
700    1_
$a Collet, Jean-Philippe $u Sorbonne University, ACTION Study Group, INSERM UMRS 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
700    1_
$a Vicaut, Eric $u Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisière (ACTION Study Group, AP-HP, Université Paris 7), Paris, France.
700    1_
$a Montalescot, Gilles $u Sorbonne University, ACTION Study Group, INSERM UMRS 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.
700    1_
$a Dudek, Dariusz $u Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
710    2_
$a ACCOAST Investigators
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 73, č. 8 (2019), s. 906-914
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30819358 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526084520 $b ABA008
999    __
$a ok $b bmc $g 1525416 $s 1096614
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 73 $c 8 $d 906-914 $e 20190305 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace